Johnson & Johnson's first-quarter 2008 results beat expectations as the US health care major saw strong sales of consumer products and a good performance in foreign markets.
During the period, net earnings totaled $3.6 billion, or $1.26 per share, versus $2.57 billion or $0.88 per share, in the first quarter of 2007, which included an after-tax in-process R&D charge of $807.0 million associated with the acquisition of Conor Medsystems (Marketletter November 27, 2006). Excluding this charge, net earnings for the current quarter and diluted earnings per share represent increases of 6.4% and 8.6%, respectively, on the year before. The weak dollar helped group revenues jump 7.7% to $16.2 billion.
Analysts polled by Thomson Financial had predicted earnings of $1.20 per share on income of $15.8 billion. According to the firm, strong group sales for the quarter are a result of the strong performance following the US launch of Zyrtec (cetirizine HCl), an over-the-counter allergy treatment; Listerine antiseptic mouthrinse and whitening products; Baby Care products; and the skin care lines Neutrogena, Clean & Clear and Aveeno.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze